Answers are grounded in this paper and cite their sources.
Pentafluorosulfanyl (SF5)-substituted polyheterocyclic architectures hold significant promise across pharmaceutical and materials science applications. Nevertheless, the lack of a general, modular synthetic strategy to convert readily available SF5-building blocks into structurally diverse SF5-polyheterocycles remains a persistent and unsolved challenge in modern heterocyclic chemistry. To address this gap, we report a single-step, atom-economical synthesis of 3-(pentafluoro-λ6-sulfanyl)-2-arylfuro[3,2-b]quinolines and 3-(pentafluoro-λ6-sulfanyl)-2arylfuro[3,2-b]pyridines. This transformation is catalyzed by inexpensive ZrCl4 and promoted by NaI, proceeding via a cascade cyclizative rearrangement: (i) regioselective 1,3-dipolar addition of quinoline or pyridine N-oxides to SF5-alkynes, (ii) sequential 1,3-oxygen transfer, and (iii) rearomatization—affording the target 3-SF5-polyheterocycles in yields up to 99%. The methodology exhibits broad functional group tolerance and practical utility, enabling late-stage diversification of drug-like molecules, modular assembly of value-added heterocyclic scaffolds, and rational construction of D–π–A-type push–pull fluorophores with enhanced photophysical properties. Collectively, this work provides a scalable, operationally simple route to SF5polyheterocycles, thereby advancing their accessible chemical space for discovery in medicinal and materials chemistry.
No takes yet. Share an insight, caveat, or question.
Yue et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: